CN 105

Drug Profile

CN 105

Alternative Names: CN-105

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator CereNova
  • Developer AegisCN; CereNova
  • Class Anti-inflammatories; Antihaemorrhagics; Apolipoprotein therapeutics; Neuropeptides; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cerebral haemorrhage

Most Recent Events

  • 02 Jun 2017 AegisCN plans a phase II trial for Cerebral haemorrhage in USA (NCT03168581)
  • 01 Aug 2016 CereNova completes phase-I clinical trials in Cerebral haemorrhage (In volunteers) in USA (IV) (NCT02670824)
  • 01 Dec 2015 Phase-I clinical trials in Cerebral haemorrhage (In volunteers) in USA (IV) (NCT02670824)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top